fda approves first oral glp-1 obesity drug august 1 2025 New GLP-1 Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity

FDA Grants Speedy Approval to Eli Lilly's Oral GLP-1 RA Drug for Obesity

27.33

★★★★☆4.8 (126)

The FDA approved a new GLP-1 pill called Foundayo (orforglipron) for adults with obesity or who are overweight and have weight-related health issues: https://bit.ly/4toaoTl

26.14

★★★★★4.9 (98)

Orforglipron, approved as Foundayo on April 1, 2026, adds another oral GLP-1 option for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. The clinical relevance

23.56

★★★★★5.0 (157)

New GLP-1 Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity

26.12

★★★★★4.7 (84)

FDA just approved orforglipron (Foundayo), Eli Lilly's oral GLP-1 receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest

21.48

★★★★★4.9 (203)

FDA Approves First ORAL GLP-1 Drug

21.44

★★★★★5.0 (176)

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro. In a major clinical trial, people taking the highest dose lost about 11% of

24.05

★★★★★4.8 (132)